53360-89-7

Usage

Uses

Used in Pharmaceutical Industry:
2-AMINO-1-(3-CHLOROPHENYL)-1-ETHANOL is used as a muscle relaxant for alleviating muscle stiffness and tension. It is applied in topical formulations to provide temporary relief from muscle discomfort by reducing muscle contractions.
Used in Cosmetics and Personal Care Industry:
2-AMINO-1-(3-CHLOROPHENYL)-1-ETHANOL is used as a preservative in cosmetics and personal care products to maintain product stability and prevent microbial growth. Its inclusion in these products helps ensure their safety and efficacy over time, while also providing a soothing effect on the skin due to its muscle-relaxing properties.

InChI:InChI=1/C8H10ClNO/c9-7-3-1-2-6(4-7)8(11)5-10/h1-4,8,11H,5,10H2

Upstream product

• 7677-24-9 trimethylsilyl cyanide 
• 587-04-2 m-Chlorobenzaldehyde 
• 454-89-7 3-Trifluoromethylbenzaldehyde 
• 39220-98-9 1-(3-chlorophenyl)-2-nitroethanol 
• 468740-86-5 2-(3-chloro-phenyl)-2-triethylsilanyloxy-ethylamine 
• 97070-75-2 2-(3-chlorophenyl)-2-hydroxyacetonitrile 
• 157028-15-4 4-(methoxymethoxy)-3,5-dimethylbenzaldehyde 

Downstream Products

• 173373-97-2 5-(3-chlorophenyl)oxazolidine 
• 101812-74-2 5-(3-chloro-phenyl)-4,5-dihydro-oxazol-2-ylamine 
• 1400670-19-0 1-(3-chlorophenyl)-N-1-{6-[8-(2-morpholin-4-ylethylamino)imidazo[1,2-a]pyrazin-3-yl]pyridin-2-yl}ethane-1,2-diamine hydrochloride 
• 1400670-07-6 1-(3-chlorophenyl)-N₁-{4-[8-(4-methylpiperazin-1-yl)imidazo[1,2-a]pyrazin-3-yl]pyrimidin-2-yl}ethane-1,2-diamine hydrochloride 
• 1400670-64-5 (2-(3-chloro-phenyl)-2-{6-[8-(2-morpholin-4-yl-ethylamino)-imidazo[1,2-a]pyrazin-3-yl]-pyridin-2-ylamino}-ethyl)-carbamic acid tert-butyl ester 
• 1400670-54-3 (2-(3-chloro-phenyl)-2-{4-[8-(4-methyl-piperazin-1-yl)-imidazo[1,2-a]pyrazin-3-yl]-pyrimidin-2-ylamino}-ethyl)-carbamic acid tert-butyl ester 
• 1386981-27-6 (S)-2-{4-chloro-3-[(2-methoxy-7-oxo-7,8-dihydro-pyrido[2,3-d]pyrimidine-6-carbonyl)amino]benzoylamino}-2-(3-chloro-phenyl-ethyl)carbamic acid tert-butyl ester 
• 1386980-14-8 2-methoxy-7-oxo-7,8-dihydro-pyrido[2,3-d]pyrimidine-6-carboxylic acid {5-[(S)-2-amino-1-(3-chloro-phenyl)ethylcarbamoyl]-2-chloro-phenyl}amide 
• 1386981-26-5 (R)-2-{4-chloro-3-[(2-methoxy-7-oxo-7,8-dihydro-pyrido[2,3-d]pyrimidine-6-carbonyl)amino]benzoylamino}-2-(3-chloro-phenyl-ethyl)carbamic acid tert-butyl ester 
• 1386980-13-7 2-methoxy-7-oxo-7,8-dihydro-pyrido[2,3-d]pyrimidine-6-carboxylic acid {5-[(R)-2-amino-1-(3-chloro-phenyl)ethylcarbamoyl]-2-chloro-phenyl}amide 
• 1269928-33-7 (S)-tert-butyl (2-amino-2-(3-chlorophenyl)ethyl)carbamate 
• 1269810-89-0 [(R)-2-amino-2-(3-chloro-phenyl)-ethyl]-carbamic acid tert-butyl ester 

Relevant academic research and scientific papers

1,6- AND 1,8-NAPHTHYRIDINES

Compounds of formula and pharmaceutically acceptable salts thereof are described, as well as the pharmaceutical compositions containing said compounds and their pharmaceutically acceptable salts, and the use of said compounds and pharmaceutical compositions for the treatment, control or amelioration of proliferative diseases, including cancer, Down syndrome or early onset Alzheimer's disease.

CARBOXYLIC ACID ARYL AMIDES

Compounds of formula and pharmaceutically acceptable salts thereof are described, as well as the pharmaceutical compositions containing said compounds and their pharmaceutically acceptable salts, and the use of said compounds and pharmaceutical compositions for the treatment, control or amelioration of proliferative diseases, including cancer.

PYRAZOLO PYRIMIDINES AS DYRK1A AND DYRK1B INHIBITORS

Compounds of formula and pharmaceutically acceptable salts thereof are described, as well as the pharmaceutical compositions containing said compounds and their pharmaceutically acceptable salts, and the use of said compounds and pharmaceutical compositions for the treatment, control or amelioration of proliferative diseases, including cancer, Down syndrome or early onset Alzheimer's disease.

PYRIDO PYRIMIDINES

Compounds of formula and pharmaceutically acceptable salts thereof are described, as well as the pharmaceutical compositions containing said compounds and their pharmaceutically acceptable salts, and the use of said compounds and pharmaceutical compositions for the treatment, control or amelioration of proliferative diseases, including cancer, Down syndrome or early onset Alzheimer's disease.

PYRAZOLO PYRIMIDINES

Compounds of formula and pharmaceutically acceptable salts thereof are described, as well as the pharmaceutical compositions containing said compounds and their pharmaceutically acceptable salts, and the use of said compounds and pharmaceutical compositions for the treatment, control or amelioration of proliferative diseases, including cancer, Down syndrome or early onset Alzheimer's disease.

IMIDAZO PYRAZINES

Compounds of formula and pharmaceutically acceptable salts thereof are described, as well as the pharmaceutical compositions containing said compounds and their pharmaceutically acceptable salts, and the use of said compounds and pharmaceutical compositio

Novel 1H-(benzimidazol-2-yl)-1H-pyridin-2-one inhibitors of insulin-like growth factor I (IGF-1R) kinase

A novel class of 1H-(benzimidazol-2-yl)-1H-pyridin-2-one inhibitors of insulin-like growth factor I (IGF-1R) kinase is described. This report discusses the SAR of 4-(2-hydroxy-2-phenylethylamino)-substituted pyridones with improved IGF-1R potency.

Design and synthesis of a functionally selective D3 agonist and its in vivo delivery via the intranasal route

This paper reports the synthesis and biological activity of a novel series of aryl-morpholine dopamine receptor agonists. Several compounds show high levels of functional selectivity for the D3 over the D2 dopamine receptor. Compound 26 has >1000-fold functional selectivity and has been successfully progressed in vivo using an intranasal delivery route.

Discovery and optimisation of potent, selective, ethanolamine inhibitors of bacterial phenylalanyl tRNA synthetase

High throughput screening of Staphylococcus aureus phenylalanyl tRNA synthetase (FRS) identified ethanolamine 1 as a sub-micromolar hit. Optimisation studies led to the enantiospecific lead 64, a single-figure nanomolar inhibitor. The inhibitor series shows selectivity with respect to the mammalian enzyme and the potential for broad spectrum bacterial FRS inhibition.

Processes for producing optically active 2-amino-1-phenylethanol derivatives

An (R)-2-amino-1-phenylethanol derivative shown by the general formula (IIa) wherein R1 and R5 represent a hydrogen atom, etc.; R2, R3 and R4 independently represent a halogen atom, etc., or a salt thereof, can readily be produced (1) by permitting a Microorganism belonging to the genus Rhodosporidium, the genus Comamonas or the like to act on a mixture of corresponding (R)-form and (S)-form to asymmetrically utilize, or (2) by permitting a microorganism belonging to the genus Lodderomyces, the genus Pilimelia or the like to act on a corresponding aminoketone derivative to asymmetrically reduce. An (R,R)-1-phenyl-2-[(2-phenyl-1-alkylethyl) amino]ethanol derivative having a high optical purity can easily be obtained from the compound of the formula (IIa) or a salt thereof. Said derivative is useful as an intermediate for producing an anti-obesity agent and so on.